Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
FDA establishment 3011742679, San Diego, California, United States. Part of Microvascular Tissue's FDA records. Every inspection FDA has posted for the site, with its outcome and cited regulations.
Inspections: 2
Official action indicated: 1
Warning letters: 1
Inspections by fiscal year
FY2018 to FY2027 to date; 1 classified OAI
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
Biologics · Human Cellular, Tissue, and Gene Therapies
4 cited references
21 CFR 211.100(a). Absence of Written Procedures Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
21 CFR 211.84(d)(1). Identity Testing of Each Component The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.
21 CFR 211.192. Investigations of discrepancies, failures There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
21 CFR 211.198(b)(2). Written record of complaint to include findings, follow-up Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.
Official Action Indicated (OAI)
Jun 9, 2017
Biologics · Human Cellular, Tissue, and Gene Therapies
None posted
No Action Indicated (NAI)
Warning letters
Letters naming this establishment; each opens the letter
An FEI (FDA Establishment Identifier) names one physical site. Inspections, outcomes and citations come from FDA's Data Dashboard; FDA posts citations only for some inspections. Recalls come from FDA's enforcement reports (iRES), one row per recall even when it covers many lots. A contract site can make products for many companies, so the company shown is the one FDA lists as the site's firm. Form 483 observations are read by Arca from the 483s FDA posts in its FOIA reading room, most of them scans: the first sentence of each observation, with redactions as FDA made them. FDA posts 483s for a minority of inspections.FDA Data Dashboard, warning letters and enforcement reports